MannKind (NASDAQ:MNKD) Hits New 12-Month Low After Earnings Miss

MannKind Corporation (NASDAQ:MNKD) reached a new 52-week low during mid-day trading on Thursday after the company announced weaker than expected quarterly earnings. The company traded as low as $3.29 and last traded at $3.50, with a volume of 36513820 shares. The stock had previously closed at $5.54.

The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The company had revenue of $111.96 million for the quarter, compared to analyst estimates of $99.85 million. MannKind had a negative return on equity of 11.12% and a net margin of 1.68%.MannKind’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 earnings per share.

Trending Headlines about MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

Wall Street Analyst Weigh In

MNKD has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of MannKind in a research note on Wednesday. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $3.50 price objective (down from $7.50) on shares of MannKind in a research report on Friday. Truist Financial set a $9.00 price target on MannKind in a research note on Monday, November 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a research report on Thursday, January 22nd. Finally, Zacks Research cut MannKind from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.21.

Insider Buying and Selling

In related news, CEO Michael Castagna sold 65,804 shares of MannKind stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $6.01, for a total transaction of $395,482.04. Following the transaction, the chief executive officer owned 2,504,792 shares in the company, valued at approximately $15,053,799.92. This trade represents a 2.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Stuart A. Tross sold 47,006 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $6.33, for a total value of $297,547.98. Following the completion of the sale, the insider owned 985,007 shares of the company’s stock, valued at approximately $6,235,094.31. The trade was a 4.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 262,846 shares of company stock valued at $1,546,840 over the last 90 days. Company insiders own 2.70% of the company’s stock.

Institutional Trading of MannKind

Several institutional investors have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV acquired a new position in MannKind during the fourth quarter worth $70,000. Voloridge Investment Management LLC grew its position in MannKind by 50.8% in the 4th quarter. Voloridge Investment Management LLC now owns 1,861,046 shares of the biopharmaceutical company’s stock valued at $10,552,000 after acquiring an additional 626,878 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in MannKind during the fourth quarter worth about $182,000. Polymer Capital Management US LLC purchased a new stake in MannKind during the fourth quarter worth about $168,000. Finally, Man Group plc lifted its position in shares of MannKind by 80.9% during the fourth quarter. Man Group plc now owns 178,494 shares of the biopharmaceutical company’s stock worth $1,012,000 after purchasing an additional 79,843 shares in the last quarter. Institutional investors and hedge funds own 49.55% of the company’s stock.

MannKind Price Performance

The company’s 50 day moving average price is $5.55 and its 200 day moving average price is $5.35. The firm has a market cap of $1.01 billion, a PE ratio of 164.08 and a beta of 0.84.

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.